DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment

Information source: Seoul National University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Epilepsy

Phase: N/A

Status: Recruiting

Sponsored by: Seoul National University Hospital

Official(s) and/or principal investigator(s):
Sang Kun Lee, MD, PhD, Principal Investigator, Affiliation: Seoul National University Hospital

Overall contact:
Sang kun Lee, MD, PhD, Email: sangkun2923@gmail.com

Summary

The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment.

Clinical Details

Official title: A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Retention rate of topiramate, levetiracetam and oxcarbazepine during 24 months of treatment

Secondary outcome:

Evaluate the confounding factors affecting the retention rate

Evaluate the response rate through seizure reduction (≥75%, ≥50%) in 2-year treatment with each antiepileptic drugs (topiramate, levetiracetam, oxcarbazepine)

Detailed description: Primary objective The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment. Secondary objective The main secondary objective of this study is to evaluate confounding factors associated with retention rate of topiramate compared with other anticonvulsants. 1. Baseline characteristics

- Seizure Type

- Gender

- Age of onset

2. Treatment regimen

- Number of concomitant medication

- Type of drug combination

- Final target dose

- Titration speed

Other secondary objectives The other secondary objectives of this study are to compare followings by each medication:

- Rate of seizure reduction (≥75%, ≥50%)

- Rate of seizure freedom

Eligibility

Minimum age: 15 Years. Maximum age: 95 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects who began their treatment with topiramate, levetiracetam or oxcarbazepine as

mono or add-on therapy with conventional drugs.

- Subjects who are with partial or generalized epilepsy

Exclusion Criteria:

- Subjects who administered combination therapy in topiramate, levetiracetam or

oxcarbazepine

- Subjects who have past experience of surgery for epilepsy treatment

- Subjects who were not followed up for at least 1 year

Locations and Contacts

Sang kun Lee, MD, PhD, Email: sangkun2923@gmail.com

Seoul National University Hospital, Seoul, Korea, Republic of; Recruiting
Sang kun Lee, MD,PhD, Email: sangkun2923@gmail.com
Jung-won Shin, MD, Email: limitsum@gmail.com
Sang kun Lee, MD, PhD, Principal Investigator
Additional Information

Related publications:

Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, Mao L, Wiegand F, Hulihan J; CAPSS-272 Study Group. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia. 2010 Oct;51(10):1970-7. doi: 10.1111/j.1528-1167.2010.02670.x.

Peltola J, Peltola M, Auvinen A, Raitanen J, Fallah M, Keränen T. Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. Acta Neurol Scand. 2009 Jan;119(1):55-60. doi: 10.1111/j.1600-0404.2008.01062.x. Epub 2008 Jun 24.

Starting date: March 2014
Last updated: March 25, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017